Clinical trial
A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With…
NCT02435433 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT02435433 |
|---|---|
| Title | A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein |
| Official title | Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ramucirumab and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein (AFP) Following First-Line Therapy With Sorafenib |
| Acronym | REACH-2 |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Hepatocellular Carcinoma |
| Intervention type | Drug |
| Interventions | Ramucirumab, Placebo |
| Enrollment | 399 |
| Start date | Jul 20, 2015 |
| Primary completion | Mar 15, 2018 |
| Completion | Nov 19, 2021 |
| First posted | May 6, 2015 |
| Last update posted | Jan 20, 2023 |
| Countries | Australia, Austria, Belgium, Brazil, Canada, China, Czechia, France, Germany, Hong Kong, Israel, Italy and 8 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: